NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

flipper, the JTM article says differently:

Patients in both arms continued to receive monthly adjuvant temozolomide (150–200 mg/m2/day×?5 days every 28 days), interspersed with the DC vaccine or placebo treatments administered on Days 0, 10 and 20, then Months 2, 4 and 8, and thereafter at 6-month intervals starting at month 12. Each DCVax-L treatment involved a dose of 2.5 million autologous tumor lysate-pulsed DCs administered intradermally in the upper arm, alternating arms between injection visits. . .
In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved ?https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

Agree that the label is a definitive source, but the label must enumerate the actual viable cells in the dose. We know that a decade ago, manual DCVax manufacturing was less than ideal, and technicians were often unable to remove a number of other immune cells. This says that at least 60% of cells in the dose were the therapeutic dendritic cells:

murcidencelum
murcidencel

autologous dendritic cells (DCs) derived from peripheral blood mononuclear cells (PBMCs) obtained from glioblastoma patients. A sample of the same patients' glioblastoma is also collected, and a tumour lysate prepared. The purified adherent monocytes isolated from PBMCs are initially grown in media containing granulocyte-macrophage colony-stimulating factor (GM- CSF) and interleukin 4 (IL-4) to induce differentiation into dendritic cells, followed by loading of the dendritic cells with the tumour lysate in culture media supplemented with GM-CSF and IL-4. The final cell suspension contains =60% dendritic cells (MHC Class II+, CD86+; CD14-), with =40% of the cells in the suspension being other autologous cells, such as T lymphocytes, B lymphocytes, and natural killer cells. The dendritic cells induce T cell proliferation in a co-stimulation assay cell therapy (antineoplastic)

https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf?sfvrsn=889fe54b_3&download=true